We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Synergy Pharmaceuticals, Inc. | NASDAQ:SGYP | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.03 | 0.0488 | 0.049 | 0 | 01:00:00 |
By Charley Grant
What's old is new again in pharma.
Bausch Health, formerly known as Valeant Pharmaceuticals, is back in the acquisitions game after a long hiatus. The company announced Wednesday that it has acquired the assets of Synergy Pharmaceuticals for $200 million. The deal gives Bausch access to Synergy's lead drug Trulance, which treats irritable bowel syndrome.
The deal is Bausch's first major acquisition since 2015. At that time, Valeant had become one of the world's most valuable drug companies by buying up troubled assets. Valeant later had to abandon that strategy because of a bloated balance sheet and heavy scrutiny of the company's sales and pricing practices.
Synergy is infamous in its own special way. The company made headlines last year when it launched the Poop Troop, a series of emojis "to allow people to better express the physical and emotional impact of chronic idiopathic constipation." Sales have largely disappointed.
Some companies are just meant to be together.
Write to Charley Grant at charles.grant@wsj.com
(END) Dow Jones Newswires
December 12, 2018 10:55 ET (15:55 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Synergy Pharmaceuticals, Inc. Chart |
1 Month Synergy Pharmaceuticals, Inc. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions